Related Experiment Video
Updated: Mar 15, 2026
Veno-Venous Extracorporeal Membrane Oxygenation in a Mouse
Published on: October 24, 2018
Is there light at the end of the tunnel?-new perspectives in ECMO survival
Federico Pappalardo1, Andrea Montisci2
1Department of Anesthesia and Intensive Care, San Raffaele Scientific Institute, Milan, Italy ;
Insights
Cardiogenic shock (CS) management is evolving with mechanical circulatory support (MCS). Early MCS intervention and improved strategies are crucial for better survival rates in patients with this critical condition.
Area of Science:
- Cardiology
- Critical Care Medicine
- Cardiovascular Surgery
Background:
- Cardiogenic shock (CS) results from impaired cardiac contractility, leading to systemic hypoperfusion.
- Acute myocardial infarction (AMI) is the primary cause of CS, carrying a high mortality rate despite advances in revascularization.
- Mechanical circulatory support (MCS) is a vital intervention for restoring perfusion and improving survival in CS patients.
Discussion:
- Identifying mortality factors in MCS patients is an active research area.
- Emerging evidence suggests early MCS intervention before multiorgan dysfunction improves outcomes.
- Challenges remain in clinical trial design and addressing unresolved questions in CS management.
Key Insights:
- MCS offers a survival benefit in cardiogenic shock by restoring systemic perfusion.
- Timely MCS implantation is critical to prevent progression to multiorgan failure.
- Research is focusing on optimizing patient selection and device strategies for CS.
Outlook:
- Future developments include earlier temporary MCS implantation and improved patient selection.
- Concomitant use of different temporary MCS devices and enhanced weaning protocols are promising.
- Durable MCS devices are increasingly utilized for destination or bridge-to-transplant therapy.
Abstract:
Cardiogenic shock (CS) is a state of systemic hypoperfusion, secondary to a deficit in cardiac contractile activity. Acute myocardial infarction (AMI) accounts for the majority of cases of CS, with a high mortality rate, despite the great improvements in revascularisation therapy. Nowadays, mechanical circulatory support (MCS) in CS often represents the only therapeutic approach able to restore systemic perfusion, determining a survival benefit. Recently, many efforts have been made to identify factors associated with mortality in patients receiving MCS devices. New insights into the pathophysiology of CS prompted the concept that the use of MCS should be considered early in the course of the disease, before the progression to multiorgan dysfunction. However, many questions remain unsolved and randomised trials in this field are hard to perform. Looking at the future, the timely implantation of temporary MCS, the correct selection of patient, the concomitant use of different temporary devices, the improvement in weaning strategies and the increasing use of durable devices as a destination or bridge therapy appear to be the most promising areas of development.
More Related Videos
03:40Point-of-Care Ultrasound for Peripheral Veno-Arterial Extracorporeal Membrane Oxygenation Without Left Ventricular Venting
Published on: January 17, 2025
09:54Lung Rapid Recovery Procurement Combined with Abdominal Normothermic Regional Perfusion in Controlled Donation after Circulatory Death
Published on: August 15, 2022
Related Concept Videos
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
01:27Pulmonary Embolism III: Nursing Management
01:29Pulmonary Embolism I: Introduction
01:30Acute Respiratory Failure-III
01:21Acute Respiratory Failure-II
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
01:23Mechanical Ventilation III: Noninvasive Ventilation
Noninvasive Positive-Pressure Ventilation...